Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw that, THX. Was on my radar after bouncing along it's 200dma in april before pulling trigger as it approached it's 8/34 crossover
RPTP(3.89) - testing 52wh following ydays buy covg & $10 tgt fm cannacord. global hunter did same w/ $6 tgt on 5/5.
NEOP(4.67) - Started "BUY" @ Morgan Joseph, tgt $9
OT/fwiw - AMIE, Ambassador Intl, owner of Windstar cruise lines has major volume today. 10 avg = 15k, today = 388,900. I bought this and tucked it away following a cruise we took w/ them . 5star total luxury, 3 vessel sailing fleet. 146 passengers/90 crew. They've been reorganizing and have 59% instituional ownership. There's no news but now back on my radar
ROFLMAO - That's the lead in to one of my favorite Bill Cosby stories, "What's In a Name" whereby his father violated that vowel rule and named he and his brother "Jesus Christ" and "Lookdamit"... "Addressing the two of us, my father would say, 'Lookdamit, stop jumping on the furniture! Jesus Christ, can't you ever be still?'...
Credit Suisse Russell index change projections... They misspelled Due in the the headline
Get Your Due Diligence On: Likely Russell 2000 Additions and Deletions
3:48 pm ET 03/03/2011- StreetInsider
Credit Suisse had a great analysis today on likely Russell 2000 entries and exits today. In total, the firm sees the number of stocks exiting the Russell 2000 lower than in past years.
Overall, they see 148 brand new additions that were not previously in the 1000, 82 names being deleted entirely from the 2000 and the 3000, 18 names moving into the Russell 1000 from the 2000, and 25 names moving from the 2000 into the 1000.
25 Biggest Stocks, By Total Market Cap, Potentially Being Added To Russell2000 (Not In Russell 1000 Previously):Quad/Graphics, Inc. (Nasdaq: QUAD), Swift Transportation Co. Inc. (Nasdaq: SWFT), Demand Media Inc. Common Stock (NYSE: DMD), Six Flags Entertainment Corp. (NYSE: SIX), Aeroflex Holding Corp. Common S (NYSE: ARX), Gold Resource Corp (Nasdaq: GORO), Chemtura Corp. Common Stock (Nasdaq: CHMT), Targa Resources Corp.Common St (Nasdaq: TRGP), Semgroup Corporation Class A Co (Nasdaq: SEMG), Verint Systems Inc. (Nasdaq: VRNT), American Assets Trust, Inc. Com (NYSE: AAT), Sterling Financial Corp. (Nasdaq: STSA), Atlantic Power Corporation (NYSE: AT), Pacific Capital Bancorp (PCBC), FXCM Inc. Class A Common Stock (Nasdaq: FXCM), Tornier N.V. (Nasdaq: TRNX), Hyperdynamics Corporation (NYSE: HDY), Accuride Corp. (NYSE: ACW), Fairpoint Communications, Inc. (FRP), KV Pharmaceutical Co. (NYSE: KV.a), Protalix Biotherapeutics, Inc. (NYSE: PLX), Kemet Corp. (NYSE: KEM), Epocrates, Inc. (Nasdaq: EPOC), Gevo, Inc. (Nasdaq: GEVO), GSI Group Inc. (Nasdaq: GSIG).
25 Biggest Stocks, By Total Market Cap, Potentially Being Deleted FromRussell 2000 (Not Going To Russell 1000):Citizens Republic Bancorp, Inc (Nasdaq: CRBC), Delta Petroleum Corp.(Nasdaq: DPTR), Kayne Anderson Energy Development Company (NYSE: KED), Thomas Properties Group Inc. (Nasdaq: TPGI), Syntroleum Corp. (Nasdaq:SYNM), Celldex Therapeutics, Inc. (Nasdaq: CLDX), GEROVA Financial Group Ltd. (NYSE: GFC), Gray Communications Systems, Inc. (NYSE: GTN), Nature's Sunshine Products, Inc. (Nasdaq: NATR), Rochester Medical Corp.(Nasdaq: ROCM), Inovio Pharmaceuticals, Inc. (NYSE: INO), Midwestone Financial Group, Inc. (Nasdaq: MOFG), John B. Sanfilippo & Son, Inc.(Nasdaq: JBSS), Asta Funding, Inc. (Nasdaq: ASFI), BlueLinx Holdings Inc. (NYSE: BXC), Build-A-Bear Workshop, Inc. (NYSE: BBW), Maxygen, Inc.(Nasdaq: MAXY), Learning Tree International, Inc. (Nasdaq: LTRE), Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), PDI, Inc. (Nasdaq:PDII), NASB Financial Inc. (Nasdaq: NASB), Argan, Inc. (AMEX: AGX), Cardionet, Inc. (Nasdaq: BEAT), R.G. Barry Corp. (Nasdaq: DFZ), Heritage Financial Group (Nasdaq: HBOS).
Stocks Potentially Moving From Russell 2000 Up To Russell 1000: Riverbed Technology Inc. (NASDAQ: RVBD), Acme Packet Inc. (NASDAQ: APKT), Rackspace Hosting Inc. (NYSE: RAX), Verifone Systems Inc. (NYSE: PAY), Brigham Exploration Co. (NASDAQ: BEXP), TIBCO Software Inc. (NASDAQ: TIBX), Molycorp Inc. (NYSE: MCP), Nordson Corporation (NASDAQ: NDSN), Rockwood Holdings Inc. (NYSE: ROC), Oasis Petroleum Inc. (NYSE: OAS), Finisar Corp. (NASDAQ: FNSR), Under Armour Inc. (NYSE: UA), Deckers Outdoor Corp. (NASDAQ: DECK), American Capital Ltd. (NASDAQ: ACAS), Sotheby's (NYSE: BID), Bruker Corporation (NASDAQ: BRKR), Westlake Chemical Corp. (NYSE: WLK), Dril-Quip Inc. (NYSE: DRQ), Fortinet Inc. (NASDAQ: FTNT), ADTRAN Inc. (NASDAQ: ADTN), Rollins Inc. (NYSE: ROL), Amerigroup Corporation (NYSE: AGP), Graftech International Ltd. (NYSE: GTI), Aruba Networks Inc. (NASDAQ: ARUN), World Fuel Services Corp. (NYSE: INT)
Stocks Potentially Moving From Russell 1000 Down To Russell 2000: The New York Times Company (NYSE: NYT), FTI Consulting, Inc. (NYSE: FCN), Office Depot, Inc. (NYSE: ODP), Exterran Holdings, Inc. (NYSE: EXH), Eagle Materials Inc. (NYSE: EXP), Hillenbrand, Inc. (NYSE: HI), International Speedway Corp. (Nasdaq: ISCA), OneBeacon Insurance Group, Ltd. (NYSE: OB), BancorpSouth, Inc. (NYSE: BXS), Central European Media Enterprises Ltd. (Nasdaq: CETV), Comstock Resources Inc. (NYSE: CRK), MDC Holdings Inc. (NYSE: MDC), Ormat Technologies Inc. (NYSE: ORA), KB Home (NYSE: KBH), Leap Wireless International Inc. (Nasdaq: LEAP), Interactive Brokers Group, Inc. (Nasdaq: IBKR), Wilmington Trust Corporation (NYSE: WL), Vishay Precision Group, Inc. (NYSE: VPG).
PLX to be added to RUSSELL 2000 per credit suisse.
Get Your Due Diligence On: Likely Russell 2000 Additions and Deletions
3:48 pm ET 03/03/2011- StreetInsider
Credit Suisse had a great analysis today on likely Russell 2000 entries and exits today. In total, the firm sees the number of stocks exiting the Russell 2000 lower than in past years.
Overall, they see 148 brand new additions that were not previously in the 1000, 82 names being deleted entirely from the 2000 and the 3000, 18 names moving into the Russell 1000 from the 2000, and 25 names moving from the 2000 into the 1000.
25 Biggest Stocks, By Total Market Cap, Potentially Being Added To Russell2000 (Not In Russell 1000 Previously):Quad/Graphics, Inc. (Nasdaq: QUAD), Swift Transportation Co. Inc. (Nasdaq: SWFT), Demand Media Inc. Common Stock (NYSE: DMD), Six Flags Entertainment Corp. (NYSE: SIX), Aeroflex Holding Corp. Common S (NYSE: ARX), Gold Resource Corp (Nasdaq: GORO), Chemtura Corp. Common Stock (Nasdaq: CHMT), Targa Resources Corp.Common St (Nasdaq: TRGP), Semgroup Corporation Class A Co (Nasdaq: SEMG), Verint Systems Inc. (Nasdaq: VRNT), American Assets Trust, Inc. Com (NYSE: AAT), Sterling Financial Corp. (Nasdaq: STSA), Atlantic Power Corporation (NYSE: AT), Pacific Capital Bancorp (PCBC), FXCM Inc. Class A Common Stock (Nasdaq: FXCM), Tornier N.V. (Nasdaq: TRNX), Hyperdynamics Corporation (NYSE: HDY), Accuride Corp. (NYSE: ACW), Fairpoint Communications, Inc. (FRP), KV Pharmaceutical Co. (NYSE: KV.a), Protalix Biotherapeutics, Inc. (NYSE: PLX), Kemet Corp. (NYSE: KEM), Epocrates, Inc. (Nasdaq: EPOC), Gevo, Inc. (Nasdaq: GEVO), GSI Group Inc. (Nasdaq: GSIG).
25 Biggest Stocks, By Total Market Cap, Potentially Being Deleted FromRussell 2000 (Not Going To Russell 1000):Citizens Republic Bancorp, Inc (Nasdaq: CRBC), Delta Petroleum Corp.(Nasdaq: DPTR), Kayne Anderson Energy Development Company (NYSE: KED), Thomas Properties Group Inc. (Nasdaq: TPGI), Syntroleum Corp. (Nasdaq:SYNM), Celldex Therapeutics, Inc. (Nasdaq: CLDX), GEROVA Financial Group Ltd. (NYSE: GFC), Gray Communications Systems, Inc. (NYSE: GTN), Nature's Sunshine Products, Inc. (Nasdaq: NATR), Rochester Medical Corp.(Nasdaq: ROCM), Inovio Pharmaceuticals, Inc. (NYSE: INO), Midwestone Financial Group, Inc. (Nasdaq: MOFG), John B. Sanfilippo & Son, Inc.(Nasdaq: JBSS), Asta Funding, Inc. (Nasdaq: ASFI), BlueLinx Holdings Inc. (NYSE: BXC), Build-A-Bear Workshop, Inc. (NYSE: BBW), Maxygen, Inc.(Nasdaq: MAXY), Learning Tree International, Inc. (Nasdaq: LTRE), Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), PDI, Inc. (Nasdaq:PDII), NASB Financial Inc. (Nasdaq: NASB), Argan, Inc. (AMEX: AGX), Cardionet, Inc. (Nasdaq: BEAT), R.G. Barry Corp. (Nasdaq: DFZ), Heritage Financial Group (Nasdaq: HBOS).
Stocks Potentially Moving From Russell 2000 Up To Russell 1000: Riverbed Technology Inc. (NASDAQ: RVBD), Acme Packet Inc. (NASDAQ: APKT), Rackspace Hosting Inc. (NYSE: RAX), Verifone Systems Inc. (NYSE: PAY), Brigham Exploration Co. (NASDAQ: BEXP), TIBCO Software Inc. (NASDAQ: TIBX), Molycorp Inc. (NYSE: MCP), Nordson Corporation (NASDAQ: NDSN), Rockwood Holdings Inc. (NYSE: ROC), Oasis Petroleum Inc. (NYSE: OAS), Finisar Corp. (NASDAQ: FNSR), Under Armour Inc. (NYSE: UA), Deckers Outdoor Corp. (NASDAQ: DECK), American Capital Ltd. (NASDAQ: ACAS), Sotheby's (NYSE: BID), Bruker Corporation (NASDAQ: BRKR), Westlake Chemical Corp. (NYSE: WLK), Dril-Quip Inc. (NYSE: DRQ), Fortinet Inc. (NASDAQ: FTNT), ADTRAN Inc. (NASDAQ: ADTN), Rollins Inc. (NYSE: ROL), Amerigroup Corporation (NYSE: AGP), Graftech International Ltd. (NYSE: GTI), Aruba Networks Inc. (NASDAQ: ARUN), World Fuel Services Corp. (NYSE: INT)
Stocks Potentially Moving From Russell 1000 Down To Russell 2000: The New York Times Company (NYSE: NYT), FTI Consulting, Inc. (NYSE: FCN), Office Depot, Inc. (NYSE: ODP), Exterran Holdings, Inc. (NYSE: EXH), Eagle Materials Inc. (NYSE: EXP), Hillenbrand, Inc. (NYSE: HI), International Speedway Corp. (Nasdaq: ISCA), OneBeacon Insurance Group, Ltd. (NYSE: OB), BancorpSouth, Inc. (NYSE: BXS), Central European Media Enterprises Ltd. (Nasdaq: CETV), Comstock Resources Inc. (NYSE: CRK), MDC Holdings Inc. (NYSE: MDC), Ormat Technologies Inc. (NYSE: ORA), KB Home (NYSE: KBH), Leap Wireless International Inc. (Nasdaq: LEAP), Interactive Brokers Group, Inc. (Nasdaq: IBKR), Wilmington Trust Corporation (NYSE: WL), Vishay Precision Group, Inc. (NYSE: VPG).
yup. followed several minutes later by 100k block & pps spike that evaporated as quickly as it appeared. HMmmmmmmmmmm
AMRN Wow 1.1M share block just went by...things that make you go Hmmmmmmmmmmm
ALXA nice pps/volume spike! news?
IMUC...I'm out, orig positions fm Dec 1.36's,
I can't be a total pig 'cuz I usually get slaughtered on these. I will revisit lower but it's just come too far for my comfort, not a fan of parabolic charts on average company pr efforts.
sommanabiyach...NVAX gets $97M HHS contract announced @ 1600. somebody leaked w/ 4 minutes before close
That's the BS that makes me crazy!!! fkrs
NVAX huge $$/Volume spike eod...news?
nothing here
IMUC again...attempting break of upper trading channel and then new yr hi, good volume too
ROFL, this quote coupled w/ Sheff's post of storyline that cannibis increases appetite in cancer patients just had to be a coincidence.....right?
I heard cannibis increases the appetite in all it's "patients", lol
PLX $9.05 Aft Mkt??? Just 1570shares, Por Que??
Anyone see news? tia
AMRN - M.Garza post fm Seeking Alpha http://seekingalpha.com/article/254714-amarin-too-many-positives-to-ignore?source=hp_wc&wc_num=1
I know he generates conflicting dialogue among many bio investers but thought this effort was more detailed than many of his other efforts. Some good food for thought.
IMUC beautiful bounce back following yday's financing announcement. On Naz top 10 gainer board since lunch.
PLX recovers fm morning raid
they started pounding it down @ 9.60
PLX perking, trying to make a break for it.
INSM 8-K : Entry into a Material Definitive Agreement.
On February 11, 2011 (the “Effective Date”), Insmed Incorporated (“Insmed”) entered into a master services agreement (the “Agreement”) with Chiltern International Inc. (“Chiltern”), a pharmaceutical development services provider. Under the terms of the Agreement, Chiltern will provide project management, clinical monitoring, data management and related services to Insmed in connection with the conduct of Phase III clinical studies of ArikaceTM (liposomal amikacin for inhalation) for treatment of cystic fibrosis (“CF”) and nontuberculous mycobacteria (“NTM”). Pursuant to work orders to be entered into by Insmed and Chiltern, Insmed will pay Chiltern for such services as provided in each work order.
The term of the Agreement is for five (5) years from the Effective Date. Insmed may terminate the Agreement or any work order at any time for any reason and without cause upon 30 days’ prior written notice. Chiltern may terminate the Agreement or any work order at any time for any reason and without cause upon 120 days’ prior written notice. In addition, either party may terminate the Agreement or any work order for a material breach of the Agreement by the other party by giving 30 days’ prior written notice of termination if such breach is not cured within the 30 days notice period. If a work order is terminated by Insmed for reasons other than an uncured material breach by Chiltern or by Chiltern on account of a material breach by Insmed, Chiltern will be entitled to receive a termination fee. Except for the termination by Chiltern as a result of an uncured material breach by Insmed, in the event of termination of the Agreement or a work order, Chiltern is required to continue to perform work under the work order for four (4) months from the date of the termination notice during which Insmed will identify an alternate service provider.
The Agreement provides for mutual representation and warranties and covenants by the parties. In addition, the Agreement requires the parties (i) to keep certain information confidential and (ii) to maintain certain insurance coverage. The Agreement also provides for an exclusivity commitment by Chiltern that it will not commence or actively seek to provide services to other third parties relating to the treatment of CF and NTM.
Under the terms of the Agreement, Chiltern is obligated to indemnify Insmed against third party claims, damages and expenses arising out of a material breach of the Agreement by Chiltern or the negligence, recklessness, omissions or intentional misconduct of Chiltern. Similarly, Insmed is obligated to indemnify Chiltern against any third party claims, damages and expenses arising out of ArikaceTM, the Phase III clinical studies of ArikaceTM or the negligence, recklessness, intentional misconduct or breaches of the Agreement by Insmed, except to the extent that such claims, damages and expenses result from negligence, recklessness, intentional misconduct, omissions or breaches of the Agreement by Chiltern.
Important Information
Insmed filed a definitive proxy statement on January 26, 2011 with the Securities and Exchange Commission (the “SEC”) to obtain shareholder approval (the “Shareholder Approval”) (i) of the conversion of the Series B Conditional Convertible Preferred Stock issued to the former holders of preferred stocks of Transave, Inc. and the issuance of Insmed’s common stock, par value $0.01 per share (the “Common Stock”), upon such conversion and (ii) to effect a one for 10 reverse stock split of Insmed’s outstanding shares of Common Stock. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE SHAREHOLDER APPROVAL. The proxy statement, any amendments or supplements to the proxy statement and other relevant documents filed by the Insmed with the SEC are available free of charge through the web site maintained by the SEC at www.sec.gov or by calling the SEC at telephone number 1-800-SEC-0330. Free copies of these documents may also be obtained from Insmed’s website at www.insmed.com or by writing to: Insmed Incorporated, 8720 Stony Point Parkway, Suite 200, Richmond, Virginia 23235, Attention: Mr. W. McIlwaine Thompson, Corporate Secretary.
Insmed and its directors and executive officers are deemed to be participants in the solicitation of proxies from the shareholders of Insmed in connection with the Shareholder Approval. Information regarding Insmed’s previous directors and executive officers is included in Insmed’s definitive proxy statement for its 2010 annual meeting of stockholders held on June 9, 2010, which was filed with the SEC on April 30, 2010. Other information regarding the participants in such proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is included in the proxy statement filed in connection with the Shareholder Approval.
IMUC - PP$/Volume Spike following today's presentation.Price and volume continue to build heading to 52wk hi
IMUC ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference
8:00 am ET 02/11/2011- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Feb. 11, 2011-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.
A webcast of the presentation will be available one hour after the presentation at http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm and will be accessible until May 16, 2011.
IMUC (2.05)ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference
8:00 am ET 02/11/2011- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Feb. 11, 2011-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.
A webcast of the presentation will be available one hour after the presentation at http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm and will be accessible until May 16, 2011.
About ImmunoCellular Therapeutics, Ltd.
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma.. The Company's “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.
IMUC ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference
8:00 am ET 02/11/2011- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Feb. 11, 2011-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.
A webcast of the presentation will be available one hour after the presentation at http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm and will be accessible until May 16, 2011.
About ImmunoCellular Therapeutics, Ltd.
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma.. The Company's “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.
IMUC pressing thru $2 on good volume
RNN nice spike on volume, breaking out, News?
IMUC volume 2.5x 10dayAvg, Price break thru $2...
IMUC move continues, starting to spike, vol last 3 days 2.5-3X avg. on no news
IMUC breakout/volume spike
IMUC - Will add w/ Break thru $1.77 ...
Started position last Dec and added thru each resistance. Lotto play, been a quiet/steady move. Nice news today.
ImmunoCellular Therapeutics Announces First Patient Enrolled In Its Phase II Trial of ICT-107
8:30 am ET 02/02/2011- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Feb. 2, 2011-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).
“The enrollment of the first patient in the Phase II trial of ICT-107 represents a hopeful step towards the development of a more effective treatment for an extremely aggressive type of brain tumor, and may ultimately result in the drastic decrease of associated rates of mortality,” said Dr. Joseph C. Landolfi, Director of Neuro-Oncology at the NJ Neuroscience Institute.
The double-blind, placebo-controlled, 2:1 randomized Phase II study is designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study will enroll approximately 100 patients and will be conducted at an estimated 15 clinical trial centers in the U.S. in collaboration with leading experts and opinion leaders in neuro-oncology.
In the Phase I clinical study of ICT-107 in GBM, newly diagnosed patients who received the vaccine in addition to the standard of care of surgery, radiation and chemotherapy demonstrated a one year overall survival of 100 percent and a two year survival of 80 percent. This compares favorably with historical 61.1 percent one-year and 26.5 percent two-year survival based on the standard of care alone. The median overall survival has not yet been reached at over 30 months analysis point, with 11 out of 16 patients alive (69% percent).
The 12-month disease-free survival from the time of surgery was 75 percent with ICT-107, compared with the historical control of 26.9 percent, and the 24 month disease-free survival with ICT-107 was 43.8 percent, compared with 10.7 percent historically. The median progression-free survival (PFS) of 16.9 months after surgery compared especially favorably with the historical median PFS of 6.9 months observed with the standard treatment. Six of the 16 patients (37 percent) who participated in the study continue to live with no disease progression with an average time of over 30 months. Safety data for ICT-107 also compared favorably to current treatments: no serious adverse events were reported and minor side effects included fatigue, skin rash and pruritis.
About ImmunoCellular Therapeutics, Ltd.
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company plans to start patient enrollment in a multi center Phase II study in Q1, 2011. The Company's “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.
Forward-Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to complete the Phase II trial for ICT-107 and to fund development of other product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for ICT-107 will not be confirmed in subsequent trials; the risk of delays in enrolling patients for, or other delays in completing, the Phase II trial for ICT-107; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or cancer stem cell vaccine or that any patents covering those vaccines will provide commercially significant protection for these technologies. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd.CEOcast, Inc.Gary Nash, 212-732-4300Investor RelationsGnash@ceocast.com
Favorite Quote: If You Say You Can or You Say You Can't, Either Way You're Right!
IMUC ramping, breakout >1.65, added
Under the radar still, been adding to initial position 1.28, @1.43 & 1.55.
Anyone else following? thoughts?
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company plans to start patient enrollment in a multi center Phase II study in Q1, 2011. The Company's “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011.
MNKD BofA/Merrill Lynch downgrade to Neutral fm Buy
BCRX attempting Breakout on lo volume, no news,
AEZS attempting breakout, very busy premkt and big volume out of the gate this am
NYMX - Big Move...liscenses European rights for experimental prostate drug
MNKD Sec Form 4 filed sending shares shooting right back up. Can someone tell me if I'm reading the Form 4 correctly in that it looks like all he did was create 700k shares @ $.01 par value to transfer to his indirect personal account per an exisisting agreement btwn MNKD and the Mann group llc?? did he really pay $8.46/share?
MNKD taken stright to the 8DMA and bounced...lookout for more from spooked daytraders.
INHX - Downgraded to Sell by Noble Financial @ 11:39...be careful
Thx Harpo eom
CYPB rejects Ramius $6 offer, CYPB liftoff